PE20161067A1 - Analogos carba-nucleosidicos para tratamiento antiviral - Google Patents
Analogos carba-nucleosidicos para tratamiento antiviralInfo
- Publication number
- PE20161067A1 PE20161067A1 PE2016000564A PE2016000564A PE20161067A1 PE 20161067 A1 PE20161067 A1 PE 20161067A1 PE 2016000564 A PE2016000564 A PE 2016000564A PE 2016000564 A PE2016000564 A PE 2016000564A PE 20161067 A1 PE20161067 A1 PE 20161067A1
- Authority
- PE
- Peru
- Prior art keywords
- carba
- treatment
- nucleosidic
- antiviral treatment
- methyltetrahydrofuran
- Prior art date
Links
- 230000000840 anti-viral effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 241000710781 Flaviviridae Species 0.000 abstract 2
- 108060004795 Methyltransferase Proteins 0.000 abstract 2
- FHOZPJTWYIPANB-NUBDZMHLSA-N (2r,3r,4r,5r)-2-(4-aminothieno[3,4-d]pyrimidin-7-yl)-5-(hydroxymethyl)-3-methyloxolane-3,4-diol Chemical compound C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1C1=C2N=CN=C(N)C2=CS1 FHOZPJTWYIPANB-NUBDZMHLSA-N 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/24—Heterocyclic radicals containing oxygen or sulfur as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/18—Acyclic radicals, substituted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/048—Pyridine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La presente invencion se refiere a compuestos analogos carba-nucleosidicos de formula I donde R1, R2, R3, R4, R5 o R6 son H, CN, NO2, entre otros; R7 es H, entre otros; R8, R9 y R10 son H, halogeno, entre otros; X2 es O, S, entre otros. Son compuestos preferidos: (2R,3R,4R,5R)-2-(4-aminotieno[3,4-d]pirimidin-7-yl)-5-(hidroximetil)-3-metilltetrahidrofuran-3,4-diol; 2-amino-7-[(2R,3R,4R,5R)-3,4-dihidroxi-5-(hidroximetil)-3-metiltetrahidrofuran-2-il]tieno[3,4-d]pirimidin-4(3H)-ona, entre otros. Tambien se refiere a una composicion farmaceutica y a un metodo de tratamiento. Dichos compuestos inhiben ARN polimerasa dependiente de ARN de VHC (RdRp) de virus de la familia Flaviviridae, siendo utiles en el tratamiento de infecciones virales por Flaviviridae
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15124809P | 2009-02-10 | 2009-02-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20161067A1 true PE20161067A1 (es) | 2016-10-23 |
Family
ID=42333309
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2016000564A PE20161067A1 (es) | 2009-02-10 | 2010-02-09 | Analogos carba-nucleosidicos para tratamiento antiviral |
| PE2011001464A PE20120257A1 (es) | 2009-02-10 | 2010-02-09 | Analogos carba-nucleosidicos para tratamiento antiviral |
| PE2016000758A PE20160858A1 (es) | 2009-02-10 | 2010-02-09 | Analogos carba-nucleosidicos para tratamiento antiviral |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2011001464A PE20120257A1 (es) | 2009-02-10 | 2010-02-09 | Analogos carba-nucleosidicos para tratamiento antiviral |
| PE2016000758A PE20160858A1 (es) | 2009-02-10 | 2010-02-09 | Analogos carba-nucleosidicos para tratamiento antiviral |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US8012942B2 (es) |
| EP (2) | EP2396340B1 (es) |
| JP (2) | JP5746638B2 (es) |
| KR (2) | KR101724759B1 (es) |
| CN (1) | CN102348713B (es) |
| AP (1) | AP2922A (es) |
| AU (3) | AU2010213873B2 (es) |
| BR (1) | BRPI1013643A2 (es) |
| CA (1) | CA2751277C (es) |
| CL (1) | CL2011001906A1 (es) |
| CO (1) | CO6420354A2 (es) |
| DK (1) | DK2396340T3 (es) |
| EA (1) | EA025085B1 (es) |
| ES (2) | ES2628842T3 (es) |
| HR (1) | HRP20140219T1 (es) |
| IL (1) | IL214396A (es) |
| MX (2) | MX345562B (es) |
| NZ (1) | NZ594370A (es) |
| PE (3) | PE20161067A1 (es) |
| PL (1) | PL2396340T3 (es) |
| PT (2) | PT2719701T (es) |
| SG (1) | SG173186A1 (es) |
| SI (1) | SI2396340T1 (es) |
| SM (1) | SMT201400056B (es) |
| UA (2) | UA112140C2 (es) |
| WO (1) | WO2010093608A1 (es) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
| DK1576138T3 (en) | 2002-11-15 | 2017-05-01 | Idenix Pharmaceuticals Llc | 2'-METHYL NUCLEOSIDES IN COMBINATION WITH INTERFERON AND FLAVIVIRIDAE MUTATION |
| AP3237A (en) | 2008-04-23 | 2015-04-30 | Gilead Sciences Inc | 1'-Substituted carba-nucleoside analogs for antiviral treatment |
| HRP20130862T1 (hr) * | 2009-09-21 | 2013-10-25 | Gilead Sciences, Inc. | Procesi i intermedijeri za pripravu analoga 1'-cijanokarbanukleozida |
| US9090642B2 (en) | 2010-07-19 | 2015-07-28 | Gilead Sciences, Inc. | Methods for the preparation of diasteromerically pure phosphoramidate prodrugs |
| SI2595980T1 (sl) | 2010-07-22 | 2014-11-28 | Gilead Sciences, Inc. | Postopki in sestavki za zdravljenje paramyxoviridae virusnih infekcij |
| PE20230684A1 (es) * | 2010-09-20 | 2023-04-21 | Gilead Sciences Inc | Analogos de carba-nucleosidos sustituidos con 2'-fluoro como inhibidores de la arn polimerasa |
| WO2012075140A1 (en) | 2010-11-30 | 2012-06-07 | Pharmasset, Inc. | Compounds |
| WO2012154321A1 (en) | 2011-03-31 | 2012-11-15 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
| WO2013030750A1 (en) | 2011-09-01 | 2013-03-07 | Lupin Limited | Antiviral compounds |
| EP2755983B1 (en) | 2011-09-12 | 2017-03-15 | Idenix Pharmaceuticals LLC. | Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections |
| TW201331221A (zh) | 2011-10-14 | 2013-08-01 | Idenix Pharmaceuticals Inc | 嘌呤核苷酸化合物類之經取代的３’，５’－環磷酸酯及用於治療病毒感染之醫藥組成物 |
| WO2013084165A1 (en) * | 2011-12-05 | 2013-06-13 | Medivir Ab | Hcv polymerase inhibitors |
| CA2862755A1 (en) | 2012-02-10 | 2013-08-15 | Lupin Limited | Antiviral compounds with a dibenzooxaheterocycle moiety |
| EP2852604B1 (en) | 2012-05-22 | 2017-04-12 | Idenix Pharmaceuticals LLC | 3',5'-cyclic phosphoramidate prodrugs for hcv infection |
| SG11201407674TA (en) | 2012-05-22 | 2014-12-30 | Idenix Pharmaceuticals Inc | D-amino acid compounds for liver disease |
| EP2852605B1 (en) | 2012-05-22 | 2018-01-31 | Idenix Pharmaceuticals LLC | 3',5'-cyclic phosphate prodrugs for hcv infection |
| PL2861611T3 (pl) | 2012-05-25 | 2017-08-31 | Janssen Sciences Ireland Uc | Nukleozydy uracylowe spirooksetanu |
| US9192621B2 (en) | 2012-09-27 | 2015-11-24 | Idenix Pharmaceuticals Llc | Esters and malonates of SATE prodrugs |
| CN104936970A (zh) | 2012-10-08 | 2015-09-23 | 埃迪尼克斯医药公司 | 用于hcv感染的2′-氯核苷类似物 |
| EP2909222B1 (en) | 2012-10-22 | 2021-05-26 | Idenix Pharmaceuticals LLC | 2',4'-bridged nucleosides for hcv infection |
| WO2014099941A1 (en) | 2012-12-19 | 2014-06-26 | Idenix Pharmaceuticals, Inc. | 4'-fluoro nucleosides for the treatment of hcv |
| WO2014137926A1 (en) | 2013-03-04 | 2014-09-12 | Idenix Pharmaceuticals, Inc. | 3'-deoxy nucleosides for the treatment of hcv |
| US9339541B2 (en) | 2013-03-04 | 2016-05-17 | Merck Sharp & Dohme Corp. | Thiophosphate nucleosides for the treatment of HCV |
| EP2970357B1 (en) | 2013-03-13 | 2025-01-01 | Idenix Pharmaceuticals LLC | Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv |
| EP2981542B1 (en) | 2013-04-01 | 2021-09-15 | Idenix Pharmaceuticals LLC | 2',4'-fluoro nucleosides for the treatment of hcv |
| WO2014197578A1 (en) | 2013-06-05 | 2014-12-11 | Idenix Pharmaceuticals, Inc. | 1',4'-thio nucleosides for the treatment of hcv |
| WO2015017713A1 (en) | 2013-08-01 | 2015-02-05 | Idenix Pharmaceuticals, Inc. | D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease |
| CN105814068B (zh) * | 2014-02-27 | 2017-08-04 | 四川海思科制药有限公司 | 一种取代的氨基磷酸酯类衍生物、其制备方法及其应用 |
| US10202411B2 (en) | 2014-04-16 | 2019-02-12 | Idenix Pharmaceuticals Llc | 3′-substituted methyl or alkynyl nucleosides nucleotides for the treatment of HCV |
| TWI740546B (zh) | 2014-10-29 | 2021-09-21 | 美商基利科學股份有限公司 | 製備核糖苷的方法 |
| ES2892123T3 (es) | 2014-12-26 | 2022-02-02 | Univ Emory | Derivados antivíricos de N4-hidroxicitidina |
| US9828410B2 (en) | 2015-03-06 | 2017-11-28 | Atea Pharmaceuticals, Inc. | β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment |
| CN107709344B (zh) * | 2015-05-01 | 2022-07-15 | 共晶制药股份有限公司 | 用于治疗黄病毒科病毒和癌症的核苷类似物 |
| LT3785717T (lt) | 2015-09-16 | 2022-04-11 | Gilead Sciences, Inc. | Coronaviridae infekcijų gydymo būdai |
| CN106083962B (zh) * | 2016-06-08 | 2018-12-18 | 成都倍特药业有限公司 | 一种具有环磷酰胺结构的化合物及其制备方法 |
| LU100724B1 (en) | 2016-07-14 | 2018-07-31 | Atea Pharmaceuticals Inc | Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection |
| EP4088725A1 (en) | 2016-09-07 | 2022-11-16 | ATEA Pharmaceuticals, Inc. | 2'-substituted-n6-substituted purine nucleotides for the treatment of a virus from the picornaviridae family |
| HRP20250266T1 (hr) | 2017-02-01 | 2025-04-25 | Atea Pharmaceuticals, Inc. | Nukleotid hemi-sulfat sol za liječenje virusa hepatitisa c |
| CN110869028B (zh) | 2017-03-14 | 2023-01-20 | 吉利德科学公司 | 治疗猫冠状病毒感染的方法 |
| CA3178212A1 (en) | 2017-05-01 | 2018-11-08 | Gilead Sciences, Inc. | Crystalline forms of (s)-2-ethylbutyl 2-(((s)-(((2r,3s,4r,5r)-5-(4-aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy) phosphoryl)amino)propanoate |
| EP3651734B1 (en) | 2017-07-11 | 2024-11-13 | Gilead Sciences, Inc. | Compositions comprising an rna polymerase inhibitor and cyclodextrin for treating viral infections |
| ES2995458T3 (en) | 2017-12-07 | 2025-02-10 | Univ Emory | N4-hydroxycytidine derivative and anti-viral uses related thereto |
| JP2021521118A (ja) | 2018-04-10 | 2021-08-26 | アテア ファーマシューティカルズ， インコーポレイテッド | 肝硬変を伴うｈｃｖ感染患者の治療 |
| CN113382994A (zh) * | 2019-02-01 | 2021-09-10 | 詹森生物制药有限公司 | 抗病毒核苷及其衍生物 |
| AU2021214911A1 (en) | 2020-01-27 | 2022-07-21 | Gilead Sciences, Inc. | Methods for treating SARS CoV-2 infections |
| US10874687B1 (en) | 2020-02-27 | 2020-12-29 | Atea Pharmaceuticals, Inc. | Highly active compounds against COVID-19 |
| CA3169340A1 (en) | 2020-03-12 | 2021-09-16 | Pavel R. Badalov | Methods of preparing 1'-cyano nucleosides |
| WO2021207049A1 (en) | 2020-04-06 | 2021-10-14 | Gilead Sciences, Inc. | Inhalation formulations of 1'-cyano substituted carbanucleoside analogs |
| CA3179226A1 (en) | 2020-05-29 | 2021-12-02 | Tomas Cihlar | Remdesivir treatment methods |
| PE20230618A1 (es) | 2020-06-24 | 2023-04-14 | Gilead Sciences Inc | Analogos de nucleosido de 1'-ciano y usos de los mismos |
| DK4204421T3 (da) | 2020-08-27 | 2024-05-27 | Gilead Sciences Inc | Forbindelser og fremgangsmåder til behandling af virale infektioner |
| EP4355319A4 (en) | 2021-06-17 | 2025-01-22 | ATEA Pharmaceuticals, Inc. | BENEFICIAL ANTI-HCV COMBINATION THERAPY |
| TWI867455B (zh) | 2022-03-02 | 2024-12-21 | 美商基利科學股份有限公司 | 用於治療病毒感染的化合物及方法 |
| US12357577B1 (en) | 2024-02-02 | 2025-07-15 | Gilead Sciences, Inc. | Pharmaceutical formulations and uses thereof |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0533833B1 (en) | 1990-06-13 | 1995-12-20 | GLAZIER, Arnold | Phosphorous produgs |
| US6312662B1 (en) * | 1998-03-06 | 2001-11-06 | Metabasis Therapeutics, Inc. | Prodrugs phosphorus-containing compounds |
| EP1225899A2 (en) | 1999-11-04 | 2002-07-31 | Virochem Pharma Inc. | Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues |
| EP1296690A2 (en) | 2000-02-18 | 2003-04-02 | Shire Biochem Inc. | METHOD FOR THE TREATMENT OR PREVENTION OF i FLAVIVIRUS /i INFECTIONS USING NUCLEOSIDE ANALOGUES |
| MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
| US20030008841A1 (en) | 2000-08-30 | 2003-01-09 | Rene Devos | Anti-HCV nucleoside derivatives |
| BR0114837A (pt) | 2000-10-18 | 2006-05-09 | Pharmasset Ltd | nucleosìdeos modificados para tratamento de infecções viróticas e proliferação celular anormal |
| EP1539188B1 (en) * | 2001-01-22 | 2015-01-07 | Merck Sharp & Dohme Corp. | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
| WO2003026675A1 (en) * | 2001-09-28 | 2003-04-03 | Idenix (Cayman) Limited | Methods and compositions for treating flaviviruses and pestiviruses using 4'-modified nucleoside |
| AT410792B (de) * | 2001-12-28 | 2003-07-25 | Dsm Fine Chem Austria Gmbh | Verfahren zur herstellung von geschützten, enantiomeren-angereicherten cyanhydrinen durch in-situ-derivatisierung |
| DK1576138T3 (en) | 2002-11-15 | 2017-05-01 | Idenix Pharmaceuticals Llc | 2'-METHYL NUCLEOSIDES IN COMBINATION WITH INTERFERON AND FLAVIVIRIDAE MUTATION |
| PT3109244T (pt) | 2004-09-14 | 2019-06-04 | Gilead Pharmasset Llc | ¿preparação de ribofuranosil pirimidinas e purinas 2¿-fluoro-2¿-alquil substituídas ou outras opcionalmente substituídas e os seus derivados |
| CN101166750A (zh) * | 2004-10-29 | 2008-04-23 | 拜奥克里斯特制药公司 | 治疗用呋喃并嘧啶类化合物和噻吩并嘧啶类化合物 |
| WO2006121820A1 (en) | 2005-05-05 | 2006-11-16 | Valeant Research & Development | Phosphoramidate prodrugs for treatment of viral infection |
| WO2007027248A2 (en) | 2005-05-16 | 2007-03-08 | Valeant Research & Development | 3', 5' - cyclic nucleoside analogues for treatment of hcv |
| AU2007338899A1 (en) | 2006-12-20 | 2008-07-03 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Nucleoside cyclic phosphoramidates for the treatment of RNA-dependent RNA viral infection |
| US20080261913A1 (en) | 2006-12-28 | 2008-10-23 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of liver disorders |
| AU2007342367B2 (en) | 2007-01-05 | 2012-12-06 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Nucleoside aryl phosphoramidates for the treatment of RNA-dependent RNA viral infection |
| ES2390188T3 (es) | 2007-01-12 | 2012-11-07 | Biocryst Pharmaceuticals, Inc. | Análogos de nucleósidos antivirales |
| DK2155758T3 (da) | 2007-05-10 | 2012-11-05 | Biocryst Pharm Inc | Tetrahydrofuro[3,4-d]dioxolanforbindelser til anvendelse i behandlingen af virusinfektioner og cancer |
| WO2010036407A2 (en) * | 2008-05-15 | 2010-04-01 | Biocryst Pharmaceuticals, Inc. | Antiviral nucleoside analogs |
-
2010
- 2010-02-09 BR BRPI1013643A patent/BRPI1013643A2/pt active Search and Examination
- 2010-02-09 PE PE2016000564A patent/PE20161067A1/es not_active Application Discontinuation
- 2010-02-09 PE PE2011001464A patent/PE20120257A1/es active IP Right Grant
- 2010-02-09 JP JP2011549324A patent/JP5746638B2/ja not_active Expired - Fee Related
- 2010-02-09 ES ES13194605.5T patent/ES2628842T3/es active Active
- 2010-02-09 EP EP10704068.5A patent/EP2396340B1/en active Active
- 2010-02-09 CA CA2751277A patent/CA2751277C/en not_active Expired - Fee Related
- 2010-02-09 AU AU2010213873A patent/AU2010213873B2/en not_active Ceased
- 2010-02-09 WO PCT/US2010/023586 patent/WO2010093608A1/en not_active Ceased
- 2010-02-09 PT PT131946055T patent/PT2719701T/pt unknown
- 2010-02-09 HR HRP20140219AT patent/HRP20140219T1/hr unknown
- 2010-02-09 EP EP13194605.5A patent/EP2719701B1/en active Active
- 2010-02-09 SG SG2011054798A patent/SG173186A1/en unknown
- 2010-02-09 ES ES10704068.5T patent/ES2453078T3/es active Active
- 2010-02-09 DK DK10704068.5T patent/DK2396340T3/en active
- 2010-02-09 KR KR1020117020990A patent/KR101724759B1/ko not_active Expired - Fee Related
- 2010-02-09 PL PL10704068T patent/PL2396340T3/pl unknown
- 2010-02-09 KR KR1020177008719A patent/KR101834707B1/ko not_active Expired - Fee Related
- 2010-02-09 MX MX2014007180A patent/MX345562B/es unknown
- 2010-02-09 UA UAA201506736A patent/UA112140C2/uk unknown
- 2010-02-09 SI SI201030554T patent/SI2396340T1/sl unknown
- 2010-02-09 US US12/702,957 patent/US8012942B2/en active Active
- 2010-02-09 NZ NZ594370A patent/NZ594370A/en not_active IP Right Cessation
- 2010-02-09 PE PE2016000758A patent/PE20160858A1/es not_active Application Discontinuation
- 2010-02-09 PT PT107040685T patent/PT2396340E/pt unknown
- 2010-02-09 CN CN201080011690.0A patent/CN102348713B/zh not_active Expired - Fee Related
- 2010-02-09 AP AP2011005818A patent/AP2922A/xx active
- 2010-02-09 MX MX2011008409A patent/MX2011008409A/es active IP Right Grant
- 2010-02-09 EA EA201190110A patent/EA025085B1/ru not_active IP Right Cessation
- 2010-09-02 UA UAA201110568A patent/UA110093C2/ru unknown
-
2011
- 2011-08-02 IL IL214396A patent/IL214396A/en not_active IP Right Cessation
- 2011-08-09 CL CL2011001906A patent/CL2011001906A1/es unknown
- 2011-08-26 CO CO11109501A patent/CO6420354A2/es active IP Right Grant
-
2014
- 2014-04-28 SM SM201400056T patent/SMT201400056B/xx unknown
- 2014-07-07 JP JP2014139374A patent/JP5951690B2/ja not_active Expired - Fee Related
-
2015
- 2015-10-06 AU AU2015238785A patent/AU2015238785B2/en not_active Ceased
-
2017
- 2017-04-12 AU AU2017202413A patent/AU2017202413B2/en not_active Ceased
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20160858A1 (es) | Analogos carba-nucleosidicos para tratamiento antiviral | |
| PE20091424A1 (es) | Nucleosidos 2',4'-sustituidos como agentes antivirales | |
| AR075584A1 (es) | COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO. | |
| CO6321235A2 (es) | Analogos de carba-nucleosidos 1 sustituidos para el tratamiento antiviral | |
| EA201500304A1 (ru) | Аналоги 2'-хлоро нуклеозидов для инфекции вгс | |
| PE20140522A1 (es) | Derivados de nucleosidos 2'- sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales | |
| AR056850A1 (es) | MÉTODOS Y KITS PARA DOSIFICAR NUCLEoSIDOS ANTIVIRALES BETA-D-2',3'-DIDEHIDRO-2',3' DIDEOXI-5-FLUOROCITIDINA | |
| SV2005001918A (es) | Metodos para preparar derivados 7-(b-d-ribofuranosilo sustituido en 2')-4 (nr2r3)-5(etin-1-ilo sustituido)-pirrol[2,3-d]pirimidina | |
| PE20060677A1 (es) | Inhibidores de la arn polimerasa dependiente de arn del virus de la hepatitis c y composiciones que los contienen | |
| ECSP12012282A (es) | Fosforamidatos de nucleósido | |
| PE20091727A1 (es) | Agentes terapeuticos antivirales | |
| EA201170915A1 (ru) | Фосфорамидатные производные гуанозиновых нуклеозидов для лечения вирусных инфекций | |
| PA8588501A1 (es) | Derivados antivirales de nucleósidos | |
| PE20160658A1 (es) | Nucleosidos sustituidos, nucleotidos y analogos de los mismos | |
| AR082068A2 (es) | Analogos de nucleosidos fluorados modificados | |
| EA200701850A1 (ru) | Соединения трициклических нуклеозидов (варианты), фармацевтическая композиция на их основе и способ лечения или профилактики вирусных инфекций у млекопитающих | |
| CO6382185A2 (es) | Compuestos nucleosidos antivirales | |
| ECSP099319A (es) | Analogos de tiofeno para el tratamiento o prevencion de las infecciones por flavivirus | |
| AR082937A1 (es) | Fosforamidatos de nucleosido | |
| CO6230992A2 (es) | Aril fosforamidatos de nucleosido y su uso como agentes antivirales para el tratamiento del virus de la hepatitis c | |
| HRP20150725T1 (hr) | Kondenzirani imidazolilimidazoli kao antivirusni spojevi | |
| SV2005001919A (es) | Compuestos nucleosidos para el tratamiento de infecciones virales | |
| UY28110A1 (es) | Derivados de nucleosido antivirales | |
| CY1115086T1 (el) | Αναλογα καρβα-νουκλεοζιτων για αντιϊικη αγωγη | |
| ECSP034699A (es) | Compuestos nucleosidos como inhibidores de polimerasa de arn viral dependiente de arn |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |